COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

ABSTRACT:

Background

Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies.

Methods

The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NS

SUBMITTER: Garassino MC 

PROVIDER: S-EPMC7292610 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature